Jardiance Drug Classification
Jardiance (empagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor 1.
Mechanism of Action
SGLT2 inhibitors work by blocking glucose reabsorption in the proximal renal tubule, which:
- Increases urinary glucose excretion (approximately 64-78 grams per day depending on dose)
- Lowers blood glucose levels independent of insulin
- Produces modest weight loss through caloric loss in urine
- Reduces blood pressure through osmotic diuresis 1
Clinical Indications
The FDA has approved Jardiance for multiple indications 1:
Primary approved uses:
- Type 2 diabetes mellitus management (as adjunct to diet and exercise)
- Reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
- Treatment of symptomatic chronic heart failure in adults (regardless of ejection fraction or diabetes status)
Position in Treatment Guidelines
According to the 2025 ADA Standards of Care, SGLT2 inhibitors like empagliflozin are prioritized for patients with specific comorbidities 2:
First-line consideration when patients have:
- Established atherosclerotic cardiovascular disease (ASCVD)
- Heart failure (both HFrEF and HFpEF)
- Chronic kidney disease
- High cardiovascular risk
The 2021 ESC/ADA/EASD integrated guidelines emphasize that empagliflozin has demonstrated consistent cardiovascular and renal benefits across multiple large trials 3. The EMPA-REG OUTCOME trial showed significant reductions in 3-point MACE, and subsequent trials (EMPEROR-Reduced, EMPEROR-Preserved) confirmed benefits in heart failure regardless of diabetes status.
Key Clinical Considerations
Cardiovascular benefits are maintained even when glucose-lowering effects diminish - continue empagliflozin for cardiovascular and kidney protection until dialysis or transplantation, even when eGFR falls below 45 mL/min/1.73 m² 2.
Important safety monitoring: